A group of proteins identified by researchers at Stockholm's KTH Royal Institute of Technology could play a role in helping multiple sclerosis patients get more accurate diagnostics about the severity and progress of their ...
Aug 14, 2013
0
0
A new strategy that dismantles a viral genome in human lung cells will ensure safe research on deadly strains of influenza, say researchers from the Icahn School of Medicine at Mount Sinai.
Aug 12, 2013
0
0
A single session of a gene therapy developed by the Universitat Autonoma de Barcelona (UAB) cures Sanfilippo Syndrome A in animal models. This syndrome is a neurodegenerative disease that affects between 1 and 9 out of every ...
Jul 2, 2013
0
0
Most of our physiological functions fluctuate throughout the day. They are coordinated by a central clock in the brain and by local oscillators, present in virtually every cell. Many molecular gearwheels of this internal ...
Jun 30, 2013
0
0
As personalized medicine is on the rise, the healthcare field is discovering the opportunities of "big data" analysis. The result of a joint project between the TUM Chair of Proteomics and Bioanalytics, SAP and the SAP Innovation ...
Jun 11, 2013
0
0
A new technology under development by an academic–industry partnership protects oral vaccines from destruction by the digestive system.
Jun 10, 2013
0
0
Irish biotechnology company Elan rejected on Monday the latest takeover bid from US group Royalty Pharma worth about $7.9 billion (6.0 billion euros).
Jun 10, 2013
0
0
In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual cells. These technologies ...
May 19, 2013
0
0
Irish drugmaker Elan Corp. PLC plans to pay $1 billion for the right to future royalties from four respiratory treatments being developed by Theravance Inc. and GlaxoSmithKline.
May 13, 2013
0
0
(AP)—French drug maker Sanofi said Thursday its net profit was slashed in the first quarter from a year earlier as falling sales and patent losses on key drugs combined to hammer earnings.
May 2, 2013
0
0
